New hope for recurrent glioblastoma: experimental drug LMP744 enters human trials

NCT ID NCT07416188

First seen Jun 25, 2026 · Last updated Jul 31, 2026 · Updated 23 times

Summary

This study tests a new drug called LMP744 in people whose glioblastoma has come back after standard treatment. The drug is designed to kill cancer cells by blocking a key growth signal and interfering with DNA repair. Participants will receive the drug through a vein for 5 days each month, and will have surgery to remove tumor tissue for analysis. The goal is to see if the drug can shrink tumors and improve survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
LMP744 (a drug that targets cancer cell growth and DNA repair)
What this could lead to
If successful, this could provide a new treatment option for people with recurrent glioblastoma, potentially shrinking tumors and extending life.
What could go wrong
This is an early-phase trial with only 40 participants, so results may not apply to everyone. The drug may not work or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • National Institutes of Health Clinical Center

    RECRUITING

    Bethesda, Maryland, 20892, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.